Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: A retrospective analysis

Journal of Clinical Immunology

Volumn 30, Issue 2, 2010, Pages 301-307

  Shapiro, Ralph ^a  

^a Midwest Immunology Clinic   (United States)

Author keywords

Infusion site reactions; Primary immune deficiency disease; Rapid push therapy; Subcutaneous immunoglobulin replacement therapy

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DEMOGRAPHY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INFUSION PUMP; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; PATIENT SAFETY; PRESCHOOL CHILD; PRIMARY IMMUNE DEFICIENCY DISEASE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; AGED; CHILD; CHILD, PRESCHOOL; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; INFUSION PUMPS; INFUSIONS, SUBCUTANEOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES;

EID: 77953535202     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-009-9352-2     Document Type: Article

References (15)

1. Gardulf A. Treatment for primary antibody deficiencies. Advantages of the subcutaneous route. BioDrugs. 2007;21(2):105-116
2. Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol. 2008;101(2):114-121
3. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am. 2008;28(2):413-437
4. Berger M. Subcutaneous IgG therapy in immune deficiency diseases. Clinical focus on primary immune deficiencies. Issue 13, February 2008. http://www.primaryimmune.org/publications/clinic-focus/cf-feb08.pdf. Accessed 28 April 2009.
5. Vivaglobin Immune Globulin Subcutaneous (Human) [package insert]. Marburg, Germany: CSL Behring GmbH; April 2007.
6. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20(2):94-100.
7. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Bock A, Costa Carvalho B, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol. 2006;26(2):177-185
8. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26(3):265-273
9. Berger M, Duff K. Subcutaneous IgG replacement therapy. Updated 4/01/2007. http://www.uhhospitals.org/Portals/0/Docs/ OurServices/Rainbow-Sub- Cu.pdf. Accessed 30 April 2009.
10. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112(1):1-7.
11. Waniewski J, Gardulf A, Hammarström L. Bioavailability of γ- globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol. 1994;14(2):90-97
12. Kittner JM, Grimbacher B, Wulff W, Jager B, Schmidt RE. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol. 2006;26(4):400-405
13. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998;79(1):48-51.
14. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Bock A, Costa-Carvalho BT, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114(4):936-942
15. Fasth A, Nystrom J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol. 2008;28(4):370-378